|
Latest Reports
|
| Date |
Description |
Country |
Analyst |
Download |
|
|
| 11-Feb-2024 |
Divis Laboratories - Opportunities galore but margins pressure continues; Remain Neutral with TP Rs 3300 |
India |
Surya Patra |
 |
| 07-Nov-2023 |
Divis Laboratories - Q2 Margin miss despite strong custom synthesis sales concerns us; Maintain NEUTRAL with TP Rs 3100 |
India |
Surya Patra |
|
| 15-Aug-2023 |
Divis Laboratories - Recovery in gross margins complements ahead: Maintain Neutral with TP Rs 3300 |
India |
Surya Patra |
|
| 20-May-2023 |
Divis Laboratories - Margin pressure to sustain in the near future; Maintain Neutral with TP Rs 2900 |
India |
Surya Patra |
|
| 05-Feb-2023 |
Divis Laboratories - Weak margins and near-term outlook concern us; Downgrade to Neutral with lowered TP Rs 2900 |
India |
Surya Patra |
|
| 08-Nov-2022 |
Divis Laboratories - Elevated cost + industry challenges mar near-term outlook; BUY in all corrections with a TP of Rs 3800 |
India |
Surya Patra |
|
| 14-Aug-2022 |
Divis Laboratories -Cost pressure on the top of FY22 high base defers re-rating; Maintain BUY with lowered TP of Rs 4500 |
India |
Surya Patra |
|
| 24-May-2022 |
Divis Laboratories - Best positioned for a steady structural growth; BUY with a TP of Rs 5500 |
India |
Surya Patra |
|
| 27-Apr-2022 |
Divis Laboratories - Covid supply opportunities likely to surprise Q4 &FY23 +Vely |
India |
Surya Patra |
|
| 13-Feb-2022 |
Divis Laboratories - Only Indian Pharma co. with 5 year of growth visibility; BUY with TP Rs 5500 |
India |
Surya Patra |
|
| 08-Nov-2021 |
Divis Laboratories - Earnings leader in difficult times as well; Upgrade to BUY with TP Rs 6000 |
India |
Surya Patra |
|
| 08-Aug-2021 |
Divis Laboratories - Growth outlook intact; value progression seems capped; Downgrade to NEUTRAL with TP Rs 5200: (PhillipCapital India) |
India |
Surya Patra |
|
| 31-May-2021 |
Divi’s Laboratories - Multi-year value growth visibility intact; BUY with TP Rs 4625 |
India |
Surya Patra |
|
| 08-Feb-2021 |
Divi’s Laboratories - Sustains multi-year value growth visibility; Maintain BUY with raised TP Rs 4200 |
India |
Surya Patra |
|
| 09-Nov-2020 |
Divi’s Laboratories - New capacity expansions provides multi-year growth visibility; Upgrade to BUY with TP Rs 4000 |
India |
Surya Patra |
|
| 10-Aug-2020 |
Divi’s Laboratories - Visible capacity expansions priced in: Neutral with TP Rs 2750 |
India |
Surya Patra |
|
| 08-Jun-2020 |
Divis Laboratories - Maintains steady performance despite challenges; Recommend BUY at corections with TP Rs 2200 |
India |
Surya Patra |
|
| 06-Feb-2020 |
Divi’s Laboratories (DIVI IN) : All set for profitable growth |
India |
Surya Patra |
|
| 06-Nov-2019 |
Divi’s Lab (DIVI IN) - Expansion and backward integration to drive value growth; Maintain BUY with raised TP Rs 2000 |
India |
Surya Patra |
|
| 26-Aug-2019 |
Divi’s Laboratories - Visible growth outlook remains robust; Maintain BUY with TP Rs 1850 |
India |
Surya Patra |
|
| 13-Aug-2019 |
Divi’s Labs (DIVI IN) - Growth outlook remains intact; Maintain BUY with TP Rs 1850 |
India |
Surya Patra |
|
| 04-Feb-2019 |
Divi’s Labs (DIVI IN) - Rides on healthy pharma outsourcing and China supply disruption: BUY with TP of Rs 1850 |
India |
Surya Patra |
|
| 29-Oct-2018 |
Divi’s Laboratories (DIVI IN) - Powered by Chinese supply disruptions, timely capex; BUY with TP of Rs 1610 |
India |
Surya Patra |
|
| 14-Sep-2018 |
Divis Laboratories- Set to benefit from Chinese supply disruptions; Upgrade to BUY with TP Rs 1550 |
India |
Surya Patra |
|
| 06-Aug-2018 |
Divi’s Labs (DIVI IN) - Recovered from all regulatory challenges; NEUTRAL with TP of Rs 1200 |
India |
Surya Patra |
|
|
|